Filing Flows › Entrada Therapeutics (TRDA) › Q4 2025
Entrada Therapeutics (TRDA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Entrada Therapeutics (TRDA) reported revenue of $1.3M for the fourth quarter 2025 (Q4 2025), -97% from a year earlier and -20% from the quarter before.
Entrada Therapeutics, Q4 2025: revenue $1.3M (-96% year over year), net loss $39.2M, operating cash flow −$32.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | -20% | -97% |
| Operating profit | −$42.2M | — | — |
| Net earnings | −$39.2M | — | — |
| Operating cash flow | −$32.2M | — | — |
What changed
Revenue was $1.3M in Q4 2025, down 97% year over year and down 20% from the previous quarter.
Operating costs exceeded revenue by $42.2M, an operating margin of -3249.3%. Total costs grew 1% against a revenue fall of 97%. The quarter ended with a net loss of $39.2M, narrower than the previous quarter's $44.1M loss.
Operating cash flow was −$32.2M. Non-cash charges added back $886K of depreciation and $4.4M of share-based compensation. Working capital and other items added $1.7M. Capital expenditures of −$207K exceeded it, leaving free cash flow of −$32.0M.
Questions
What was Entrada Therapeutics' revenue in the fourth quarter 2025?
Entrada Therapeutics (TRDA) reported revenue of $1.3M for the fourth quarter 2025 (Q4 2025), -97% from a year earlier and -20% from the quarter before.